News

Australasian company finds major formulation error with cold and flu products

AFT Pharmaceuticals has identified a major error with the formulation of over 1,300 cold and flu products used around the world.

Read More

AFT targets $15 billion pain relief market

AFT Pharmaceuticals, a 100 per cent New Zealand owned company, has researched and developed a novel therapy which represents a breakthrough in pain relief.

Read More

Maxigesic Pain Relief now available in Australia

Launched this month, MAXIGESIC® is the first analgesic that combines both Paracetamol and Ibuprofen to be registered for use in Australia.

Read More

AFT Group Sales Growth continues at +40%

Growth of 40% per annum continues for AFT Pharmaceuticals in the Australasian market (Australia and NZ) with sales for this year due to break $22 million per annum.

Read More

Impressive clinical trial results for Maxigesic

AFT Pharmaceuticals has now concluded a pivotal clinical study of 408 patients in the US and NZ. The study will form the basis of AFT’s first filing with the United States Food and Drug Administration for its flagship analgesic Maxigesic

Read More

Martindale announces AFT as distribution partner for Asia Pacific

Martindale announces AFT as distribution partner for Asia Pacific

Read More

Many Australian pharmacists have concerns about OTC codeine-based analgesics

Some text

Read More

NZ pharmacists concerned about codeine-based analgesics

Some text

Read More

Doctors have alternatives to topical antibitoc treatments

Some text

Read More

Maxigesic wins best new product award in Australia

This month Maxigesic picked up the the ‘Best New Product’ award at the 2014 National Convention and Exhibition of the Pharmacy Guild.

Read More

Kiwi Co. pops pill into US$20b pain-relief market

New Zealanders will find a home-grown answer to pain relief on the shelves at their local pharmacy this month with the launch of a new drug that represents a world breakthrough.

Read More